Prostate cancer

News

Wales expands NHS use of AI for cancer diagnosis

The devolved Welsh Government plans to expand the use of an artificial intelligence-powered tool used to spot cancer in biopsy samples, after seeing a 13% increase in pros

News

Pfizer joins three-way PARP battle in prostate cancer

Pfizer has won FDA approval for its PARP inhibitor Talzenna in castration-resistant prostate cancer (CRPC) in a combination that it hopes will help it challenge AstraZenec

News

Lynparza set for narrow prostate cancer use after FDA vote

AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US.

News

J&J claims first approval for PARP combo Akeega

Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and anti-androgen therapy, as a treatm

News

Lynparza gets OK for use in prostate, breast cancers on NHS

AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed

News